Navigation Links
Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good,Pharmacokinetics and Tolerability in Phase I/II Trial

nt reduction in absolute lymphocyte count of 48% that persisted for approximately two weeks. The etiology of this finding is uncertain at this time given the lack of measured telomerase inhibition in this patient.

"We are encouraged by the results," said Dr. Colowick. "The first and only telomerase inhibitor in clinical trials continues to demonstrate predictable pharmacokinetics over the range investigated and appears to be well tolerated. We will apply what we are learning to the continued dose escalation as we move further into the predicted therapeutic dose cohorts for both the CLL and solid tumor trials. Furthermore, we are adding two additional sites for the CLL trial to accelerate patient enrollment."

"Based on preclinical data demonstrating the effects of GRN163L on both mature and cancer stem cells in multiple myeloma, Geron will initiate a clinical trial involving multiple myeloma patients," continued Dr. Colowick. "In addition, the company will begin a fourth trial of GRN163L in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer. The basis for this trial is the result of promising preclinical animal data demonstrating the drug's activity in this tumor type as well. Geron expects to initiate both trials in the coming months."

Background

Geron's ongoing Phase I/II trial is a sequential cohort, dose escalation study to determine the safety and tolerability of GRN163L administered intravenously on a weekly basis to patients with refractory or relapsed CLL. Patients interested in enrollment into the trial should visit the Patient Information page of Geron's website at www.geron.com.

Telomerase is a broadly applicable and critical tumor target. It is expressed in a broad array of malignant tumors, essential for malignant cell growth and absent or expressed transiently at low levels in most normal adult tissues.

GRN163L is a short chain oligonucleotide that is unique in its resistance
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
2. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
3. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
4. Telomerase Presentations at the AACR 2007 Annual Meeting
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
7. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
8. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
9. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
10. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
(Date:5/23/2013)... 23, 2013 Nephros, Inc. (OTC Bulletin Board: ... company that develops and sells high performance liquid purification ... offering.  In addition, the concurrent temporary reduction in exercise ... May 17, 2013. Nephros estimates that it ... rights offering.   A portion of the proceeds will be ...
(Date:5/23/2013)... May 23, 2013  MGC Diagnostics Corporation (NASDAQ: ... technology company, today scheduled a conference call to discuss ... year 2013, ended April 30, 2013. The call will ... 2013. The Company will report financial results for the ... close on Thursday, May 30, 2013. ...
(Date:5/23/2013)... Tenn. , May 23, 2013  TeamHealth ... 24-hour nurse triage and nurse advice lines, announces ... committee, comprising physician, nursing and administrative leaders, provides ... safe, quality and cost-effective services for hospital clients, ... our national healthcare system evolves, it,s imperative to ...
Breaking Medicine Technology:Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2TeamHealth Medical Call Center Forms Clinical Advisory Committee 2
... High-dose ursodeoxycholic acid detrimental for treatment of primary sclerosing cholangitis ... national team of researchers led by scientists at Mayo Clinic has ... liver disease, is not helpful for patients, according to a study ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090105/MAYOLOGO ...
... , ZURICH, Aug. 27 /PRNewswire/ -- ... of four phase III trials have been published in the prestigious peer-reviewed ... roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations ... COPD is an under-diagnosed progressive lung disease that may lead ...
Cached Medicine Technology:Researchers Find High-Dose Therapy for Liver Disease Not Effective 2Researchers Find High-Dose Therapy for Liver Disease Not Effective 3Researchers Find High-Dose Therapy for Liver Disease Not Effective 4Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 2Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 3Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 4Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 5Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 6Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 7Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 8Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 9
(Date:5/24/2013)... 24, 2013 Mike Stoler believes that ... successful business people in New York. That’s why ... weekly on CUNY TV. And that’s why he ... Allergy Associates, LLP (ENTA)—the largest single specialty practice in ... throat, allergy and audiology specialists and sub-specialists service communities ...
(Date:5/24/2013)... May 24, 2013 According to a May ... Social Media Leads to Spikes in Plastic Surgery ... a growing prevalence of facial plastic surgery and ... people have become keenly aware of the need to look ... as Facebook, Google and even Skype's video chat feature (Go ...
(Date:5/24/2013)... one in five parents think they have little control ... illicit drug use, a new U.S. government survey finds. ... Abuse and Mental Health Services Administration (SAMHSA), since new ... most influential forces helping to shape their child,s views ... show that parents can make an enormous difference in ...
(Date:5/24/2013)... aortic valve implantation (TAVI) is effective and safe in ... results from a multicentre Asian registry reported at EuroPCR ... a treatment option for selected patients with symptomatic severe ... North American or European centres," Paul Chiam, senior consultant ... conference. He explained that it is unknown whether the ...
(Date:5/24/2013)... Fit Yummy Mummy, a fitness program that ... trying to get rid of the belly fat in ... women who want to combine exercises with nutrition has ... Stevenson, prompting an investigative review. , “Holly's Rigsby's program ... variety of motivational strategies, nutritional plans, proper diets, and ...
Breaking Medicine News(10 mins):Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 3Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 4Health News:Facebook and Google – Is Social Media Driving Demand for Plastic Surgery? 2Health News:Parents Underestimate Influence Over Teens' Substance Abuse: Survey 2Health News:Registry confirms TAVI efficacy and safety in Asian patients 2Health News:Fit Yummy Mummy: Review Examining Holly Rigsby’s Fitness Program Released 2
... Washington, D.C., and Meet with Elected,Officials, WASHINGTON, March ... Washington, D.C., this April 1 to meet with,congressional leaders ... Disabilities Act, support for epilepsy public health,programs and more ... is one of 50 young people with epilepsy participating ...
... D.C., and Meet With Elected,Officials, WASHINGTON, March 14 ... D.C., this April 1 to meet with,congressional leaders and ... Act, support for epilepsy public health,programs and more research ... one of 50 young people with epilepsy participating in,Kids ...
... DENVER, March 14 Birner Dental Management,Services, Inc. ... dental practices,announced its regular quarterly dividend. The Company,s ... of 17 cents per share of common,stock. The ... of record,March 28, 2008., Birner Dental Management ...
... ( http://www.nhs.uk ), the,digital ,front door, to ... package on,pregnancy, aimed at helping people find ... Based on NHS accredited information, the pregnancy ... staying healthy and fit during pregnancy,including eating ...
... STE ) today announced that its Board ... $300 million in shares of STERIS common stock. ... of,February 29, 2008. This share repurchase authorization replaces ... Through March,13, 2008, the Company has repurchased approximately ...
... that processed vermiculite tainted with asbestos-like fibers that originated from ... and thickening of the membrane that lines the chest wall ... those who were exposed at or below current legal levels. ... times its original size when rapidly heated and has a ...
Cached Medicine News:Health News:Utah Youth Named National Epilepsy Spokesperson 2Health News:Tennessee Youth Named National Epilepsy Spokesperson 2Health News:STERIS Corporation Announces New $300 Million Share Repurchase Authorization 2Health News:STERIS Corporation Announces New $300 Million Share Repurchase Authorization 3Health News:Legal exposure to asbestos-like material linked to lung damage 25 years later 2Health News:Legal exposure to asbestos-like material linked to lung damage 25 years later 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: